Richard K Yang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7388343/publications.pdf Version: 2024-02-01



RICHARD K YANG

#	Article	IF	CITATIONS
1	<scp>Nonâ€coding <i>NOTCH1</i></scp> mutations in chronic lymphocytic leukemia negatively impact prognosis. American Journal of Hematology, 2022, 97, .	4.1	1
2	Landscape of NOTCH1 mutations and co-occurring biomarker alterations in chronic lymphocytic leukemia. Leukemia Research, 2022, 116, 106827.	0.8	1
3	Geriatric Oncology Workshop (GrOW): Development and Evaluation of a Nationwide Nursing Curriculum. Journal of Geriatric Oncology, 2021, 12, 649-657.	1.0	4
4	Endometrial biomarkers in premenopausal women with obesity: an at-risk cohort. American Journal of Obstetrics and Gynecology, 2021, 224, 278.e1-278.e14.	1.3	7
5	TP53 variant allele frequency correlates with the chemotherapy response score in ovarian/fallopian tube/peritoneal high-grade serous carcinoma. Human Pathology, 2021, 115, 76-83.	2.0	1
6	CBFB Break-Apart FISH Testing: An Analysis of 1629 AML Cases with a Focus on Atypical Findings and Their Implications in Clinical Diagnosis and Management. Cancers, 2021, 13, 5354.	3.7	3
7	Clinical Applications of Chromosomal Microarray Testing in Myeloid Malignancies. Current Hematologic Malignancy Reports, 2020, 15, 194-202.	2.3	7
8	Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2. Clinical Cancer Research, 2020, 26, 3296-3306.	7.0	12
9	T-Cell Repertoire in Combination with T-Cell Density Predicts Clinical Outcomes in Patients with Merkel Cell Carcinoma. Journal of Investigative Dermatology, 2020, 140, 2146-2156.e4.	0.7	14
10	Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies. Oncotarget, 2020, 11, 600-618.	1.8	15
11	A Cryptic BCR-PDGFRB Fusion Resulting in a Chronic Myeloid Neoplasm With Monocytosis and Eosinophilia: A Novel Finding With Treatment Implications. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1300-1304.	4.9	4
12	Expression pattern of androgen receptor and AR-V7 in androgen-deprivation therapy–naÃ⁻ve salivary duct carcinomas. Human Pathology, 2019, 84, 173-182.	2.0	15
13	Improving bone marrow biopsy quality through peer discussion and data comparisons: A single institution experience. International Journal of Laboratory Hematology, 2018, 40, 419-426.	1.3	3
14	Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma. Cancer Immunology, Immunotherapy, 2018, 67, 1647-1658.	4.2	25
15	<i>In Situ</i> Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments. Cancer Research, 2016, 76, 3929-3941.	0.9	120
16	Bone Marrow Biopsy Quality: A Quality Improvement Project to Identify Factors Affecting Bone Marrow Biopsy Length and Find Strategies to Improve Overall Biopsy Quality. Blood, 2015, 126, 3323-3323.	1.4	2
17	A pilot trial of hu14.18-IL2 in patients with completely resectable recurrent stage III or stage IV melanoma Journal of Clinical Oncology, 2014, 32, 9044-9044.	1.6	3
18	Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the Hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival. Cancer Immunology, Immunotherapy, 2013, 62, 1303-1313.	4.2	44

RICHARD K YANG

#	Article	IF	CITATIONS
19	Intratumoral Delivery of Low Doses of Anti-CD40 mAb Combined With Monophosphoryl Lipid A Induces Local and Systemic Antitumor Effects in Immunocompetent and T Cell-Deficient Mice. Journal of Immunotherapy, 2013, 36, 29-40.	2.4	25
20	Intratumoral hu14.18–IL-2 (IC) Induces Local and Systemic Antitumor Effects That Involve Both Activated T and NK Cells As Well As Enhanced IC Retention. Journal of Immunology, 2012, 189, 2656-2664.	0.8	64
21	Tumor-associated myeloid cells can be activated in vitro and in vivo to mediate antitumor effects. Cancer Immunology, Immunotherapy, 2012, 61, 1683-1697.	4.2	14
22	The anti-tumor effect of resveratrol alone or in combination with immunotherapy in a neuroblastoma model. Cancer Immunology, Immunotherapy, 2011, 60, 731-738.	4.2	24
23	Soluble interleukinâ€2 receptor α activation in a Children's Oncology Group randomized trial of interleukinâ€2 Therapy for Pediatric Acute Myeloid Leukemia. Pediatric Blood and Cancer, 2011, 57, 398-405.	1.5	13
24	Correlations between in situ denitrification activity and nir-gene abundances in pristine and impacted prairie streams. Environmental Pollution, 2010, 158, 3225-3229.	7.5	72
25	Genotypes of NK Cell KIR Receptors, Their Ligands, and FcÎ ³ Receptors in the Response of Neuroblastoma Patients to Hu14.18-IL2 Immunotherapy. Cancer Research, 2010, 70, 9554-9561.	0.9	163
26	Anti-GD2 strategy in the treatment of neuroblastoma. Drugs of the Future, 2010, 35, 665.	0.1	57
27	Clinical and Serologic Interleukin 2 Receptor α Response to Interleukin-2 in CCC-2961, a Ranomized Phase 3 Trial for Pediatric Acute Myeloid Leukemia Blood, 2008, 112, 959-959.	1.4	1
28	Abundance of six tetracycline resistance genes in wastewater lagoons at cattle feedlots with different antibiotic use strategies. Environmental Microbiology, 2007, 9, 143-151.	3.8	297
29	Quantification of Tetracycline Resistance Genes in Feedlot Lagoons by Real-Time PCR. Applied and Environmental Microbiology, 2004, 70, 7372-7377.	3.1	167